Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Plasma Protein Therapeutics Industry?

There has been significant growth in the size of the plasma protein therapeutics market lately. A rise from $32.22 billion in 2024 to $34.68 billion in 2025 is projected, with a compound annual growth rate (CAGR) of 7.6%. The increase in the past period can be linked to a higher occurrence of rare illnesses, a growing aged population, increased global blood plasma availability, a surge in hemophilia cases, enhanced diagnostic methods, and a conducive regulatory setting.

Anticipated robust growth in the upcoming years is set for the plasma protein therapeutics market, which is projected to reach a total value of $45.58 billion by 2029, reflecting a compound annual growth rate (CAGR) of 7.1%. Projections for this growth in the given timeframe can be assigned to advancements in gene therapy, a rise in healthcare spending, extended indications, precision medicine methodologies, and patient access schemes. Leading trends for this forecasted period encompass innovations in technology, the popularization of telemedicine, advanced developments in plasma fractionation, the discovery of next-generation therapies, the integration of recombinant therapies, and the surge of personalized medicine strategies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

What Forces Are Driving The Growth Of The Plasma Protein Therapeutics Industry?

The escalating frequency of autoimmune disorders is anticipated to drive the expansion of the plasma protein therapeutics market in the future. An autoimmune disorder manifests when the human immune system wrongfully attacks and demolishes healthy body cells. Autoimmune diseases are managed through therapeutic plasma exchange, a process elicited when the body falsely recognizes part of itself as alien and generates proteins (termed as autoantibodies) that erroneously attack the misrecognized body part. For example, a research carried out by the University of Glasgow, a public university in the UK, with a sample size of 22 million people in May 2023 found that nearly 10% of the UK’s population is affected by autoimmune disorders, surpassing past estimates. Consequently, the ascending frequency of autoimmune disorders is propelling the augmentation of the plasma protein therapeutics market in the future.

What Is The Overview Of Market Segmentation In The Plasma Protein Therapeutics Industry?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

What Future Market Trends Are Projected For The Plasma Protein Therapeutics Industry?

Product advancements are becoming a prominent trend in the plasma protein therapeutic market. Primary firms present in this sector are centering their efforts on product innovation to establish a competitive upper hand in the marketplace. To exemplify, Octapharma AG, a company based in Switzerland, received an endorsement from European medical regulators in October 2023 for their lyophilized form of their popular product, octaplasLG. This improved preparation is tailor-made for pre-hospital transfusion, offering a practical and powerful treatment for healthcare professionals to manage patients in crucial conditions. This approval emphasizes Octapharma’s dedication to improving patient treatment by implementing inventive solutions in the domain of blood products.

Who Are The Primary Players Operating Across The Global Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market include CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., New York Blood Center, Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Australian Red Cross Lifeblood

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Which Region Offers The Most Growth Potential For The Plasma Protein Therapeutics Market Through 2029?

North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9213&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model